These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 1463414

  • 1. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension.
    Camras CB, Schumer RA, Marsk A, Lustgarten JS, Serle JB, Stjernschantz J, Bito LZ, Podos SM.
    Arch Ophthalmol; 1992 Dec; 110(12):1733-8. PubMed ID: 1463414
    [Abstract] [Full Text] [Related]

  • 2. PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension.
    Villumsen J, Alm A.
    Br J Ophthalmol; 1992 Apr; 76(4):214-7. PubMed ID: 1390487
    [Abstract] [Full Text] [Related]

  • 3. A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure.
    Lusky M, Ticho U, Glovinsky J, Weinberger D, Nesher R, Yassur Y, Melamed S.
    Ophthalmology; 1997 Oct; 104(10):1720-4. PubMed ID: 9331215
    [Abstract] [Full Text] [Related]

  • 4. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes.
    Ziai N, Dolan JW, Kacere RD, Brubaker RF.
    Arch Ophthalmol; 1993 Oct; 111(10):1351-8. PubMed ID: 8216015
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2 alpha-isopropyl ester analogues for glaucoma treatment.
    Hotehama Y, Mishima HK.
    Jpn J Ophthalmol; 1993 Oct; 37(3):259-69. PubMed ID: 8295363
    [Abstract] [Full Text] [Related]

  • 6. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
    Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M.
    Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
    [Abstract] [Full Text] [Related]

  • 7. Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients.
    Camras CB, Siebold EC, Lustgarten JS, Serle JB, Frisch SC, Podos SM, Bito LZ.
    Ophthalmology; 1989 Sep; 96(9):1329-36; discussion 1336-7. PubMed ID: 2780003
    [Abstract] [Full Text] [Related]

  • 8. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.
    Toris CB, Camras CB, Yablonski ME.
    Ophthalmology; 1993 Sep; 100(9):1297-304. PubMed ID: 8371915
    [Abstract] [Full Text] [Related]

  • 9. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers.
    Alm A, Villumsen J.
    Arch Ophthalmol; 1991 Nov; 109(11):1564-8. PubMed ID: 1755739
    [Abstract] [Full Text] [Related]

  • 10. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma.
    Hotehama Y, Mishima HK, Kitazawa Y, Masuda K.
    Jpn J Ophthalmol; 1993 Nov; 37(3):270-4. PubMed ID: 8295364
    [Abstract] [Full Text] [Related]

  • 11. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
    Stjernschantz J, Selén G, Astin M, Resul B.
    Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group.
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [Abstract] [Full Text] [Related]

  • 16. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study.
    Rácz P, Ruzsonyi MR, Nagy ZT, Bito LZ.
    Arch Ophthalmol; 1993 May; 111(5):657-61. PubMed ID: 8489449
    [Abstract] [Full Text] [Related]

  • 17. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure.
    Rulo AH, Greve EL, Hoyng PF.
    Br J Ophthalmol; 1994 Dec; 78(12):899-902. PubMed ID: 7819171
    [Abstract] [Full Text] [Related]

  • 18. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM, McGavin JK, Culy CR, Ibbotson T.
    Drugs Aging; 2003 Dec; 20(8):597-630. PubMed ID: 12795627
    [Abstract] [Full Text] [Related]

  • 19. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure.
    Friström B, Nilsson SE.
    Arch Ophthalmol; 1993 May; 111(5):662-5. PubMed ID: 8489450
    [Abstract] [Full Text] [Related]

  • 20. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
    Aung T, Chew PT, Yip CC, Chan YH, See JL, Khng CG, Hoh ST, Ng LH, Lee HM.
    Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.